Resumen

ORDONEZ-BOSCHETTI, Laura et al. Clinical considerations on the introduction of ocrelizumab in Mexico. Rev. mex. neurocienc. [online]. 2020, vol.21, n.3, pp.97-103.  Epub 25-Oct-2021. ISSN 2604-6180.  https://doi.org/10.24875/rmn.20000153.

Multiple sclerosis (MS) is the leading cause of neurological disability among young adults. The disease-modifying treatments (DMTs) have been a breakthrough in the care of this patients, becoming a treatable disease. Today, we face a broad spectrum of treatment possibilities, which should be used rationally to provide the maximum benefit for the patients. In the context of the introduction of ocrelizumab as a treatment option in the Mexican MS DMT portfolio, a group of neurologists was convened to analyze the potential transition among DMT from their experience, through a desk research and expert opinion. As a result, here we describe the different considerations suggested for switching from different DMT to ocrelizumab that includes profiling studies, washout periods, and follow-up considerations. We concluded that the switch from other DMT previously used to ocrelizumab could be convenient and safe, as long as there is an adequate selection and profiling of the patients.

Palabras llave : Drug switching; Expert opinion; Mexico; Multiple sclerosis; Ocrelizumab; Disease-modifying treatment.

        · resumen en Español     · texto en Inglés     · Inglés ( pdf )